SCHEMBL5060302

SCHEMBL5060302

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4cnccc4c3)cc2)ccn1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 6/20 0.78
MAPK14 Q16539 5/20 0.78
MAPK13 O15264 4/20 0.63
ABL1 P00519 6/20 0.63
RAF1 P04049 4/20 0.63
SRC P12931 3/20 0.63
AXL P30530 2/20 0.63
MAPK11 Q15759 2/20 0.63
KDR P35968 2/20 0.63
RIPK1 Q13546 2/20 0.63
PTK2 Q05397 2/20 0.63
PLK4 O00444 1/20 0.63
ACOX3 O15254 1/20 0.63
MAP3K7 O43318 1/20 0.63
DYRK3 O43781 1/20 0.63
JAK2 O60674 1/20 0.63
ERN1 O75460 1/20 0.63
RPS6KA4 O75676 1/20 0.63
STK10 O94804 1/20 0.63
MAP4K4 O95819 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5052223 0.90 ABL1 (0.76) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL5056329 0.90 BRAF (0.78) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL5062213 0.88 BRAF (0.60) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL2214703 0.88 BRAF (1.00) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL5056389 0.88 BRAF (0.76) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL2081819 0.88 BRAF (0.76) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL5062242 0.87 BRAF (0.75) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL2081838 0.87 MAPK14 (0.75) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL2243347 0.87 BRAF (0.89) BRAFMAPK14MAPK13ABL1RAF1
SCHEMBL5059981 0.87 ABL1 (0.82) BRAFMAPK14MAPK13ABL1RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 BRAF 2/4885MAPK14 100/4885MAPK13 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.